Generic placeholder image

Drug Delivery Letters

Author(s): Manza M. Priyanka, Shinde A. Ujwala, Sheth M. Kalyani and Namita Desai*

DOI: 10.2174/2210303111666210812160624

DownloadDownload PDF Flyer Cite As
In situ Gels of Acylovir Nanoemulsions for Improved Delivery to the Eye

Page: [265 - 273] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: Acyclovir, BCS Class III drug is commercially available as 3% w/w eye ointment for multiple applications. Acyclovir nanoemulsions can be proposed to reduce dose because of improved permeation characteristics. Further, the development of in situ ophthalmic gels can be advantageous to reduce the number of applications due to increased mucoadhesion and sustaining effect.

Objective: The purpose of this study was the development and evaluation of nanoemulsions based in situ gels of Acyclovir (1% w/w) as potential ophthalmic delivery systems.

Methods: Nanoemulsions of Acyclovir were developed by Phase Inversion Temperature method using Capmul MCM, stearyl amine and Kolliphor RH 40 as liquid lipid, charge inducer and surfactant, respectively selected on the basis of Acyclovir solubility in the oil phase and emulsification ability of surfactants. These nanoemulsions were further developed into in situ ophthalmic gels using gellan gum and Methocel K4M.

Results: The developed gels showed a sustained effect in vitro release studies and improved goat corneal permeation in ex vivo studies when compared to marketed ointment. HET-CAM studies concluded the absence of irritation potential, while in vivo irritation study in Wistar rats showed the absence of erythema and swelling of eyes after visual inspection for 72 hours. Histopathological studies on isolated rat corneas showed no abnormalities in anterior corneal epithelium and corneal stroma without any epithelial hyperplasia. Acyclovir nanoemulsions based in situ ophthalmic gel showed increased corneal deposition and permeation in isolated rat eyes.

Conclusion: The improved potential of developed ophthalmic gels was proven due to the reduced frequency of application compared to the marketed ointment in animal studies.

Keywords: Acyclovir, nanoemulsions, ophthalmic, in situ mucoadhesive gels, rat corneal drug deposition.

Graphical Abstract

[1]
Mandell, C.L.; Alfred, G.G. Chemotherapy of Microbial Diseases. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th ed; McGraw Hill, 2008; pp. 813-814.
[2]
Rang, H.; Dale, M.; Ritter, J.; Flower, R. Antiviral Agents in Rang & Dale’s Pharmacology Churchill Livingstone, 6th ed; , 2007, pp. 684-691.
[3]
Jain, S.P. Twice a day ocular inserts of acyclovir by melt extrusion technique. Indian J. Pharm. Sci., 2007, 69(4), 562-567.
[http://dx.doi.org/10.4103/0250-474X.36945]
[4]
Solans, C. Nano-emulsions. Curr. Opin. Colloid Interface Sci., 2005, 10, 102-110.
[http://dx.doi.org/10.1016/j.cocis.2005.06.004]
[5]
Souza, J.G.; Dias, K.; Pereira, T.A.; Bernardi, D.S.; Lopez, R.F. Topical delivery of ocular therapeutics: carrier systems and physical methods. J. Pharm. Pharmacol., 2014, 66(4), 507-530.
[http://dx.doi.org/10.1111/jphp.12132] [PMID: 24635555]
[6]
Ko, D.Y. Recent progress of in situ formed gels for biomedical applications. Prog. Polym. Sci., 2013, 38, 672-701.
[http://dx.doi.org/10.1016/j.progpolymsci.2012.08.002]
[7]
Almeida, H.; Amaral, M.H.; Lobão, P.; Lobo, J.M. In situ gelling systems: A strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov. Today, 2014, 19(4), 400-412.
[http://dx.doi.org/10.1016/j.drudis.2013.10.001] [PMID: 24120893]
[8]
Pouton, C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur. J. Pharm. Sci., 2000, 11(Suppl. 2), S93-S98.
[http://dx.doi.org/10.1016/S0928-0987(00)00167-6] [PMID: 11033431]
[9]
Baka, E.; Comer, J.E.; Takács-Novák, K. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J. Pharm. Biomed. Anal., 2008, 46(2), 335-341.
[http://dx.doi.org/10.1016/j.jpba.2007.10.030] [PMID: 18055153]
[10]
Date, A.A.; Nagarsenker, M.S. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int. J. Pharm., 2007, 329(1-2), 166-172.
[http://dx.doi.org/10.1016/j.ijpharm.2006.08.038] [PMID: 17010543]
[11]
Anton, N.; Vandamme, T.F. The universality of low-energy nano-emulsification. Int. J. Pharm., 2009, 377(1-2), 142-147.
[http://dx.doi.org/10.1016/j.ijpharm.2009.05.014] [PMID: 19454306]
[12]
Anton, N.; Vandamme, T.F. Nano-emulsions and micro-emulsions: Clarifications of the critical differences. Pharm. Res., 2011, 28(5), 978-985.
[http://dx.doi.org/10.1007/s11095-010-0309-1] [PMID: 21057856]
[13]
Sahoo, S.K.; Dilnawaz, F.; Krishnakumar, S. Nanotechnology in ocular drug delivery. Drug Discov. Today, 2008, 13(3-4), 144-151.
[http://dx.doi.org/10.1016/j.drudis.2007.10.021] [PMID: 18275912]
[14]
Carlfors, J.; Edsman, K.; Petersson, R.; Jörnving, K. Rheological evaluation of Gelrite in situ gels for ophthalmic use. Eur. J. Pharm. Sci., 1998, 6(2), 113-119.
[http://dx.doi.org/10.1016/S0928-0987(97)00074-2] [PMID: 9795027]
[15]
Tavaszi, J.; Budai, P. The use of HET-CAM test in detecting the ocular irritation. Commun. Agric. Appl. Biol. Sci., 2007, 72(2), 137-141.
[PMID: 18399434]
[16]
Kapanigowda, U.G.; Nagaraja, S.H.; Ramaiah, B. Enhanced trans-corneal permeability of valacyclovir by polymethacrylic acid copolymers based ocular microspheres: In vivo evaluation of estimated pharmacokinetic/pharmacodynamic indices and simulation of aqueous humor drug concentration-time profile. J. Pharm. Innov., 2016, 11, 82-91.
[http://dx.doi.org/10.1007/s12247-015-9239-0]
[17]
Tayel, S.A.; El-Nabarawi, M.A.; Tadros, M.I.; Abd-Elsalam, W.H. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int. J. Pharm., 2013, 443(1-2), 293-305.
[http://dx.doi.org/10.1016/j.ijpharm.2012.12.049] [PMID: 23333217]
[18]
Gallarate, M.; Chirio, D.; Bussano, R.; Peira, E.; Battaglia, L.; Baratta, F.; Trotta, M. Development of O/W nanoemulsions for ophthalmic administration of timolol. Int. J. Pharm., 2013, 440(2), 126-134.
[http://dx.doi.org/10.1016/j.ijpharm.2012.10.015] [PMID: 23078859]
[19]
Gillet, A.; Compère, P. Liposome surface charge influence on skin penetration behavior. Int. J. Pharm, 2011, 411(1-2), 223-231.
[20]
Gilleron, L.; Coecke, S.; Sysmans, M.; Hansen, E.; van Oproy, S.; Marzin, D.; van Cauteren, H.; Vanparys, P. Evaluation of the HET-CAM-TSA method as an alternative to the draize eye irritation test. Toxicol. In Vitro, 1997, 11(5), 641-644.
[http://dx.doi.org/10.1016/S0887-2333(97)00074-X] [PMID: 20654364]